logo
Why are orange cats orange? A small missing piece of DNA is why, 2 new studies explain

Why are orange cats orange? A small missing piece of DNA is why, 2 new studies explain

Yahoo17-05-2025
Orange cats may be known for their silly behavior, but two new studies are a step closer to understanding "the why" behind the furry felines' coloring.
Two independent studies published on May 15 by geneticists in Japan and from Stanford University in California explain how orange cats' coloring is a direct result of a missing DNA code near a specific protein found within the X chromosome. Inherently, the studies also explain why most orange cats, about 80%, are male.
So, to answer the question: What makes orange cats orange? Here's a deeper look into the findings of the two studies.
Furry felines: We know why cats knead. But here's why humans love it so much.
Both studies found that a small missing piece of DNA code located next to the Rho GTPase-activating protein (ARHGAP36) resulted in orange fur coloration. In cats, ARHGAP36 is responsible for fur coloration.
When this piece of DNA is missing, it causes ARHGAP36 to become more abundant, roughly 10 times more abundant, Gregory Barsh, Stanford University genetics professor and study co-author, told USA TODAY. This leads to the production of more red, orange or yellow pigment, which is incorporated into a cat's hair.
This type of mutation is "very unusual," according to Barsh.
"Most mutations ... like genetic conditions in humans ... (are) inactivate or take away the function of a gene," Barsh said. "But what this does is really different. It increases the expression of this gene ARHGAP36, and moreover, it does it in a specific type of cell, the pigment cell ... that is found in hair, eye and skin color."
So why does this happen? Why does an increased amount of ARHGAP36 result in orange fur?
"It's interfering with a central signaling pathway, a hormonal signaling pathway that's present in many, many cells of the body ... basically all animals," Barsh said. "That is a hormonal signaling pathway that ... normally produces black or brown pigment. What increased expression of a ARHGAP36 does it is destroys that signaling pathway, or it inhibits that signaling pathway. So instead, the melanocytes (cells that form melanin) make red or yellow pigment."
Most orange cats are male, about 80%, to be more exact, according to the Regional Animal Protection Society. And the findings from the recent studies make sense of why.
ARHGAP36 is found within the X chromosome. Females have two X chromosomes, and males have an X chromosome and a Y chromosome. For the mutation to appear in female cats, it would need to occur in both X chromosomes, which has a lesser chance of occurring than in a male's one X chromosome.
Watch: Fabulous feline stories on International Cat Day
Learning about the ARHGAP36 mutation goes beyond just understanding cats.
The gene is found in all animals, including humans, Barsh said. Learning how it functions allows researchers to better understand hormonal signaling pathways as a general phenomenon.
As cat lovers, Barsh said he and his research team worked with volunteers and nonprofit organizations to collect the samples necessary for their study.
First, the team worked with cat owners to obtain voluntary samples. Barsh said the study's lead author, Stanford University genetics professor Christopher Kaelin, went to several cat shows and asked owners if he could swab their cats' cheeks for samples.
The team also partnered with spay and neuter clinics to study tissue samples. In some cases, when a female cat is neutered, she is already pregnant, Barsh said, adding that the fetal tissue, or the embryonic tissue, gets discarded. When partnering with clinics, Barsh and his team collected these tissue samples instead to use for their study.
While the two studies were completed independently, Barsh said the researchers have been in contact with each other for the last year and decided to publish in the same peer-reviewed journal, "Current Biology," on the same day.
Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@usatoday.com.
This article originally appeared on USA TODAY: Why are orange cats orange? A missing piece of DNA explains why
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Yahoo

time32 minutes ago

  • Yahoo

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Partnership includes joint collaboration initiatives to improve precision medicine and accelerate innovation in cancer pathology BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact or visit 1AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer Media Contact Owen Blaschak LifeSci Communications oblaschak@

Brookfield Zoo welcoming new polar bear this fall
Brookfield Zoo welcoming new polar bear this fall

CBS News

time35 minutes ago

  • CBS News

Brookfield Zoo welcoming new polar bear this fall

A new polar bear is coming to Chicago's Brookfield Zoo. The zoo is welcoming 8-year-old Amelia Gray, coming from Oregon. She will join the polar bears Hope and Hudson later this fall. "We look forward to welcoming Amelia Gray to Brookfield Zoo Chicago, as her arrival is a powerful opportunity to educate the community of the critical need to protect this vulnerable species," said Mark Wanner, associate vice president of animal care and conservation at Brookfield Zoo Chicago. Zoo officials said polar bears were the first species to be listed as threatened under the Endangered Species Act. They said this was primarily due to climate change.

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Associated Press

time35 minutes ago

  • Associated Press

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight ® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact [email protected] or visit 1 AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer [email protected] Media Contact Owen Blaschak LifeSci Communications [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store